By otakuyassine3@gmail.com 
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CEO Christopher Peetz sold 9,102 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the transaction, the chief executive officer now directly owns 115,920 shares in the company, valued at $5,589,662.40. This trade represents a 7.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Christopher Peetz also recently made the following trade(s):
- On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $327,629.04.
- On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $320,678.98.
Mirum Pharmaceuticals Stock Performance
Shares of MIRM traded up $1.62 during mid-day trading on Tuesday, hitting $50.21. 410,214 shares of the company’s stock were exchanged, compared to its average volume of 511,828. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm has a market capitalization of $2.41 billion, a P/E ratio of -24.86 and a beta of 0.96. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $50.34. The business’s 50 day moving average is $44.39 and its two-hundred day moving average is $42.02.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm’s revenue was up 89.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.57) earnings per share. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.
Institutional Investors Weigh In On Mirum Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. lifted its position in shares of Mirum Pharmaceuticals by 1.2% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock valued at $256,245,000 after acquiring an additional 75,000 shares during the period. State Street Corp lifted its position in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares during the period. Geode Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after acquiring an additional 29,017 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at approximately $28,913,000. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at approximately $19,473,000.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Leerink Partners raised their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Citigroup raised their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $57.10.
View Our Latest Stock Analysis on MIRM
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Recommended Stories
Receive News & Ratings for Mirum Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.